Myocardial perfusion scanning plays a significant role in diagnostic and therapeutic decision making in cardiac disease. These refer to a group of non-invasive imaging tests that can be performed to help clinicians assess blood flow to areas of myocardium. Obtaining information on perfusion and metabolite uptake from myocardium plays a vital role in determining the appropriate medical treatment or intervention for optimizing one's cardiac health. These tests are useful for diagnostic and prognostic purposes throughout a variety of clinical settings, including evaluating symptoms concerning for angina, to rule out acute coronary syndrome as a cause of chest pain, assessing therapeutic outcome after interventions, as well as for assessing for viable or scarred myocardium. With such information, clinicians can appropriately understand a patient's coronary health, perform risk stratification for future cardiovascular events, assess for therapeutic response to interventions correcting perfusion defects, and allow for prognostication.
Perfusion scanning utilizes various radiotracers, which are administered to the patient and allowed to distribute to multiple tissues. These radiotracers emit photons, which are detectable with a gamma camera which typically contains a single sodium iodide crystal (Single photon emission computed tomography, or SPECT) or multiple crystals (typically used in positron emission tomography, or PET) to interact with captured photons. These cameras contain a collimator, which helps eliminate background, and a photomultiplier, which translate the interactions between the photon and crystals into electrical energy to produce images. In SPECT imaging techniques, common radiotracers used include thallium-201 or technetium-based radiotracers, including technetium-99m sestamibi or technetium-99m tetrofosmin. Thallium-201 is distributed actively into myocardial cells, whereas technetium-based products are distributed passively depending on blood flow and myocardial viability. These radiotracers are injected when the heart is stressed, either by exercise or pharmacologically. The uptake of radiotracer indicates areas of perfusion and viable tissue during stress and at rest. Areas of poor perfusion display improved perfusion during rest, termed reversible ischemia.
SPECT, which is more commonly used and available in clinical practice today, uses planar images to reconstruct a three-dimensional representation of myocardial perfusion. Unlike planar imaging, SPECT can obtain sequential slices without overlap of normal and abnormal areas with improved resolution over planar imaging . SPECT imaging has undergone validation in multiple large scale studies for detection of coronary artery disease; however, there are some limitations to this imaging modality. These include artifacts such as those caused by motion, attenuation, or extracardiac activity affecting the quality of images and reader variability. Also, SPECT imaging typically uses technetium-99m tracers, which have low first-pass extraction, and thus leading to the underestimation of ischemic changes both in extent and severity.
PET imaging, although less available than SPECT, can help overcome some of these limitations. PET images have better spatial resolution and allow for attenuation correction more accuracy than SPECT. With the high temporal resolution, PET scanning also allows for quantification of myocardial blood flow and myocardial flow reserve and can be of great utility in risk stratification in assessing cardiovascular mortality. Further, PET imaging has the advantages of protocols requiring less time, less radiation exposure compared to SPECT imaging techniques. In PET imaging, radiotracers such as ammonia N-13, rubidium-82, and flurpiridaz F-18 are radiotracers used in for myocardial perfusion imaging. Rubidium-82 is used commonly and can produce good quality images as it has a 65% myocardial extraction rate. In contrast, ammonia N-13 and fluripiridaz F-18 have a myocardial extraction rate of 80% and 95% respectively, therefore producing better quality images with higher resolution. The downside of the later radiotracers is the need for an on-site cyclotron. Rubidium-82 is usable for pharmacologic stress testing, whereas ammonia-N-13 and flurpiridaz F-18 can be used for both exercise and pharmacologic stress testing.
To obtain stress images, exercise or pharmacologic testing can is an option. Common pharmacologic agents used include regadenoson, adenosine, and dipyridamole. All three medications work by causing coronary vasodilatation, with subsequent blood flow differences. Adenosine and dipyridamole are A-2A as well as A-1, A-2B, and A-3 receptor agonists, which can also cause bronchospasm, AV nodal block, chest tightness, and flushing. Regadenoson is a selective A-2A agonist which can be a choice in patients with known bronchospasms. Thus, regadenoson is the most common pharmacological agent used in clinical practice.